Literature DB >> 9433867

The presence of masked antiribosomal P autoantibodies in healthy children.

C J Anderson1, B R Neas, Z Pan, E Taylor-Albert, M Reichlin, H A Stafford.   

Abstract

OBJECTIVE: To determine if antiribosomal P (anti-P) autoantibodies are present in healthy children.
METHODS: Sera from healthy children were screened for anti-P by conventional enzyme-linked immunosorbent assay and immunoblot techniques. Sera were also treated with immobilized ribosomal P antigens on nitrocellulose strips; affinity-purified fractions were tested for anti-P by high-sensitivity immunoblot. The relative binding affinities were compared for affinity-purified anti-P antibodies from healthy children and adults, and patients with systemic lupus erythematosus. IgG fractions of anti-P-depleted sera from healthy children were assessed for inhibition of autologous anti-P activity.
RESULTS: Conventional serologic screening showed no IgG nor IgM anti-P in 88 untreated sera. IgG anti-P were unmasked in all 79 sera treated by the membrane batch affinity technique. IgM anti-P were identified in 27 of the treated sera; the percentage of positive sera decreased with increasing age (chi(2) for linear trend P = 0.00081). Affinity-purified anti-P from children had relative binding affinities similar to those of anti-P from other groups. Sera from healthy children contained inhibitory IgG antibodies to anti-P.
CONCLUSION: These results show that anti-P autoantibodies are present in all healthy children. The majority of these autoantibodies are masked by IgG antibodies, suggesting concordant development of a regulatory network.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9433867     DOI: 10.1002/1529-0131(199801)41:1<33::AID-ART5>3.0.CO;2-5

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

1.  The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-gamma) production by murine splenocytes.

Authors:  M Soto; C Alonso; J M Requena
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 2.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

3.  Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults.

Authors:  Z J Pan; C J Anderson; H A Stafford
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

4.  The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes.

Authors:  Shilpa Oak; Lisa K Gilliam; Mona Landin-Olsson; Carina Törn; Ingrid Kockum; Christina R Pennington; Merrill J Rowley; Michael R Christie; J Paul Banga; Christiane S Hampe
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-26       Impact factor: 11.205

Review 5.  Hidden autoantibodies.

Authors:  M Lorber; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2000-02       Impact factor: 10.817

6.  Reactivity against complementary proteinase-3 is not increased in patients with PR3-ANCA-associated vasculitis.

Authors:  Henko Tadema; Cees G M Kallenberg; Coen A Stegeman; Peter Heeringa
Journal:  PLoS One       Date:  2011-03-17       Impact factor: 3.240

7.  Anti-idiotypic antibody specific to GAD65 autoantibody prevents type 1 diabetes in the NOD mouse.

Authors:  Xin Wang; Aixia Zhang; Yu Liu; Shi Chen; Zhenqing Feng; Wenbin Shang; Marlena Maziarz; Jared Radtke; Christiane S Hampe
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

8.  Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies.

Authors:  Harini Bagavant; Antonina M Araszkiewicz; Jessica K Ingram; Katarzyna Cizio; Joan T Merrill; Cristina Arriens; Joel M Guthridge; Judith A James; Umesh S Deshmukh
Journal:  Front Immunol       Date:  2021-05-28       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.